Here are the top 10 learning points from the elegant review of right ventricle failure by: Ryan J Tedford MD, Evan Brittain and Brian Houston MD:

Historical achievement and major step to improve access to care in the largest public hospital network in the US: The First TAVR at NYC Health + Hospitals/Bellevue improving health disparities while doing what we love! Norma Keller Sripal Bangalore Samuel Bernard NYU Grossman School of Medicine Glenn Fishman

Exercise-Induced Left Atrial Hypertension in Heart Failure With Preserved Ejection Fraction - ScienceDirect ⁦Sanjiv J. Shah, MD⁩ sciencedirect.com/science/articl…

Heart Failure vs Interventional Cards Who would win? Find out at our CME NYU Grossman School of Medicine Register now: bit.ly/NYUHFCME2023 🔥 Free for all trainees! 🔥 Sripal Bangalore Alex Reyentovich, MD #CardioEd #CardioTwitter #GDMTworks

#ISHLT2023 is coming up, but let’s get back to basics. Do you know when your HF patient is advanced? Register NOW NYU Grossman School of Medicine bit.ly/NYUHFCME2023 🪐 Stellar guests!💫 🔥FREE for all trainees!⚡️ Robert Mentz, MD #CardioEd #CardioTwitter #MedEd #ISHLT

What an all-star panel. Abhinay Ramachandran doing an excellent job presenting a complex LVAD case highlighting the difficulty of helping our patients with CKD and high BMI. Robert Mentz, MD Jason N. Katz Randal Goldberg #BestOutcomes

Case and Controversies NYU Langone Health where Jason N. Katz with an excellent talk about cardiogenic shock. Swan-Ganz has a place, if you know how to use them! #preach #cardiogenicshock Bernard Kadosh Alex Reyentovich, MD

Scleroderma cardiomyopathy is under-recognized and difficult to treat. Congrats to Samuel Maidman, MD NYU Grossman School of Medicine for highlighting this extremely challenging case. Great images! cvcasejournal.com/article/S2468-… CV Case Journal American Society of Echocardiography Randal Goldberg

This one was a real labor of love. PACs a/w lower mortality in shock! Thanks to Robert Roswell Dave Morrow David Berg Erin Bohula Jason N. Katz Shashank Sinha, MD, MSc, FACC, FAHA, FHFSA and many more below! #CardioTwitter #CardioEd #cardiogenicshock #SwansRise jacc.org/doi/10.1016/j.…

Bellevue is the only public hospital in the U.S. with an ECMO treatment program. The program was fast tracked & launched during the height of the COVID pandemic. “What if we could save just one life? That’s what drove us.” - Dr. Norma Keller, Dir of Cardiology

Pig to human heart transplantation in 2 BD deceased human recipients. Really amazing to be a part of the team.

🏨 with HFrEF 35% risk of ☠️ in the first year post-🏨 discharge 💊 ⬇️ ☠️ to 25% 💊💊 ⬇️ ☠️ to 16% 💊💊💊 ⬇️ ☠️ to 12% 💊💊💊💊 ⬇️ ☠️ to 9% ☠️ ARR 26% with 💊💊💊💊 ✅ NNT to save a life = 4 with 💊💊💊💊 💸 Quadruple Rx cost effective

Proud to present results of the Donor Heart Study! Of 4,333 brain dead donors, 13% had LV dysfunction. This was usually reversible and had no impact on heart tx recipient survival. Another reason to #StartWithYes ahajournals.org/doi/10.1161/CI… Stanford Heart Failure, Cardiac Transplant and MCS Jeff Teuteberg Eldrin Lewis

How do you safely biopsy a #XenoHeart when the anatomy isn’t straightforward? Very carefully. Had a great time at #IXASanDiego2023 presenting our technique using TEE guidance. #echofirst #xenotransplantation #Sandiegomeeting2023 NYU Langone Health NYU Grossman School of Medicine

Rehabilitative Medicine is coming up at 6amET. Jonathan Whiteson is talking #heartfailure with Randal Goldberg, #cardiacrehab with Dr. Matthew Vorsanger #heartdefects with Dr. Adam Small. Give us a call at 877-698-3627. siriusxm.us/DoctorRadio

Thanks to The ISHLT for inviting me to share our work on CAV waitlist mortality. 🚨 Spoiler alert 🚨 It’s bad. CAV at Status 4 should be Status 3 CAV at Status 3 should be Status 2 #ISHLT2024 #transplant

Less than a month away! bit.ly/NYUAHF24 Trainee code for FREE registration: 21824resifellow Attending code for 50% off: 21824local

Going to be a great conference, excellent lineup, and some novel talks Bernard Kadosh has planned

Amazing collaboration, not just for a groundbreaking xenotransplantation, but also for a never reported (that I'm aware of) renal transplant after LVAD implantation. Both aspects can prove to be helpful for a very sick population with few options.

Recently published REALM-DCM a phase 3 international study on a disease modifying treatment for LMNA cardiomyopathy. While a negative trial, shows the future of our field with therapies targeting specific mutations! #GenesMatter #BenefitOfTesting ahajournals.org/doi/epdf/10.11…